Exosomal NKp30-ligand BAG6 is crucial for detection of tumor cells by NK cells in vitro and in vivo. Soluble plasma factors including BAG6 suppress NK cell cytotoxicity and promote evasion of CLL cells from NK cell anti-tumor activity. Abstract Natural killer (NK) cells are a major component of the anti-tumor immune response. NK cell dysfunctions have been reported in various hematological malignancies, including chronic lymphocytic leukemia (CLL). Here we investigated the role of tumor cell-released soluble and exosomal ligands for NK cell receptors that modulate NK cell activity. Soluble CLL plasma factors suppressed NK cell cytotoxicity and downregulated the surface receptors CD16 and CD56 on NK cells of healthy donors. The inhibition of NK cell cytotoxicity was attributed to the soluble ligand BAG6/BAT3 that engages the activating receptor NKp30 expressed on NK cells. Soluble BAG6 was detectable in the plasma of CLL patients, with the highest levels at advanced disease stages. In contrast, NK cells were activated when BAG6 was presented on the surface of exosomes. The latter form was induced in non-CLL cells by cellular stress via an nSmase2-dependent pathway. Such cells were eliminated by lymphocytes in a xenograft tumor model in vivo. Here, exosomal BAG6 was essential for tumor cell killing because BAG6-deficient cells evaded immune detection. Taken together, the findings show that the dysregulated balance of exosomal versus soluble BAG6 expression may cause immune evasion of CLL cells.
Introduction CLL patients suffer from severe immune defects resulting in increased susceptibility to infections and failure to generate an anti-tumor immune response 1 . NK cells, lymphocytes of the innate immune system, are considered as a major component of the immunosurveillance in leukemia [2] [3] [4] . However, little is known about the functionality of NK cells and their role in tumor immune escape in CLL.
NK cells are tightly regulated by inhibitory or activating "missing self" and "induced self" signals sensed via cell surface receptors 5 . The best examined activating receptors are the Fc receptor CD16 (FcγRIII), NKG2D and the Natural Cytotoxicity Receptors (NCRs) NKp30, NKp44 and NKp46. Known ligands for NKG2D are the MHC class I related molecules MICA/B and the UL16-binding proteins (ULBP1-6) that are induced upon cellular stress on target cells 6, 7 . Only few ligands for the NCRs have been identified to date [8] [9] [10] [11] [12] [13] [14] . Surprisingly, among novel ligands for NKp30 (BAG6 (BAT3) 10 , B7-H6 11 ), NKp44 (PCNA 12 ) and NKp46 (vimentin 13, 14 ), only B7-H6 is a surface membrane ligand. BAG6, PCNA and vimentin are proteins without any classical transmembrane domain and known to exert divergent intracellular functions, including protein sorting and transport, proliferation and apoptosis. It is still not clear how these intracellular proteins are exposed to surface NK cell receptors.
Recently it was shown that NK cells display a poor cytolytic activity against CLL cells, which could be restored with IL-2/IL-15 15 but the mechanisms for NK cell suppression or anergy remain to be elucidated. The NKG2D expression on NK cells in CLL was not significantly altered in comparison to healthy donors [15] [16] [17] although it was reported that CLL patients have high serum levels of soluble NKG2D ligands. Shedding of NKG2D ligands from the surface of tumor cells represents an evasion strategy to escape from NK cell-mediated recognition and killing in hematological and solid
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From tumors 18, 19 . Among the activating NK cell receptors only NKp30 expression was significantly reduced on NK cells in CLL patients 15 . This is interesting since NKp30 is a receptor not only involved in direct target cell killing but also responsible for the interaction with dendritic cells, which represents the link to the adaptive immune response [21] [22] [23] . Under certain conditions and by mechanisms that are not completely understood, BAG6 can be released from cells into the extracellular environment 10, 24, 25 . The protein can be expressed on the surface of exosomes to engage NKp30 and to activate NK cells 10, 25 . Exosomes are 50-100 nm microvesicles that originate from intracellular multivesicular bodies and are produced by many cell types 26, 27 . The inducible formation and release of exosomes depends on the DNA damage-induced p53-dependent secretory pathway [28] [29] [30] .
To address the role of NKp30 and its ligand BAG6 for immunosurveillance in CLL, we analyzed the release of BAG6 from tumor cell lines and CLL cells, and the BAG6dependent modulation of NK cell activity. We demonstrate in vitro and in vivo that BAG6 plays an important role in recognition and killing of tumor cells by NK cells and provide a possible explanation for the reduced efficacy of NK cells in CLL patients.
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 
Material and Methods

Human samples
Enzyme-linked immunosorbent assay (ELISA)
The mouse monoclonal 3E4 (raised against the BAG6 N-terminus) and the BAG6specific rabbit serum 4160 10 were used to detect BAG6. MICA, MICB, MIF and ULBP2 were measured with commercial ELISA kits (R&D Systems, Wiesbaden, Germany). Details of protocol deviations are given in the supplements.
Flow cytometry
The following reagents were used: mouse anti-human CD9, monoclonal mouse antihuman-BAG6, and annexinV-PE. As secondary antibody PE goat anti-mouse was Primary NK cells were stained with FITC-or PE-labeled antigen-specific antibodies against NKG2D, NKp30, NKp44, NKp46, CD16, CD56 and the activation marker CD69 and analyzed using a FACSCalibur (Beckton Dickinson, Heidelberg, Germany) with FlowJo software (Treestar, Ashland, OR, USA). Antibody details see supplement.
Transgenic cells
MCF7 cells overexpressing nSmase2 were described previously 31 . Knockdown of nSmase2 was achieved using specific siRNA (QIAGEN, Hilden, Germany). The lentiviral particle production and transduction of 293T cells for BAG6 knockdown were achieved with the Mission® shRNA Vector pLKO.1-puro System using shRNA Plasmid TRC7354 (Sigma-Aldrich, Munich, Germany). Experimental procedures were carried out according to the manufacturers' instructions. BAG6-GFP-fusion sequences were cloned into the vector pEGFP-C1 (Clontech, Mountain View, CA, USA).
Cytotoxicity Assays
NK cells were left untreated or pre-incubated for 20-48 hours with 25 % serum in IMDM, recombinant BAG6 (10ng/ml, Abcam) or with exosomes purified from 293T cells prior standard cytotoxicity assays 10 . Blocking antibodies or Fc constructs were added as indicated (10 µg/ml).
Exosome preparation
Exosome production, purification via centrifugation and the coupling to beads for flow cytometry was described previously 25 . In brief, cells were cultured in media with exosome-depleted FCS (100.000 xg for 90min). The supernatant was centrifuged for 10 min at 300 xg and twice for 15 min at 6.800 xg to remove cell fragments.
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Exosomes were pelleted twice at 100.000 xg for 90 min with intermediate resuspension in PBS. The amount of exosomal protein was quantified by Nanodrop1000 (Thermo Scientific, Schwerte, Germany). Plasma samples were diluted 1:1 in PBS prior to exosome purification.
Western Blotting
Cells were lyzed in lysis buffer (50mM Tris-HCl pH 8, 150mM NaCl, 0.5% Triton X-100, 0.5% DOC, protease inhibitors). Protein concentration was measured with a BCA Protein Assay Kit. 10 to 30 µg were loaded onto SDS-PAGE gels for blotting using standard methods (see Suppl. Table 1 ). 
In vivo experiments
Statistical analysis
Data were analyzed with GraphPad Prism 5 (San Diego, CA, USA) and appropriate statistical tests were chosen as indicated in the figure legends. Bar diagrams are presented as mean plus SEM.
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Results
Tumor cell lines release BAG6 via a nSmase2-dependent exosomal pathway.
We investigated the exosomal pathway responsible for the BAG6 release in MCF7 cells. We chose MCF7 cells as model, as these are p53-proficient and characterized by low endogenous expression of the TNFalpha-inducible enzyme neutral sphingomyelinase 2 (nSmase2, SMPD3). Both p53 and nSmase2 are mandatory for exosome formation [28] [29] [30] 32 . Here, overexpression of nSmase2 resulted in a robust release of BAG6-expressing exosomes, which were not detectable in the parental wild type cell line ( Next, BAG6 full length protein was fused to a GFP reporter gene to test whether the expression of BAG6 on exosomes was the result of an active translocation. The GFP control and the GFP-BAG6 fusion protein were expressed at comparable levels in transfected 293T cells (Fig.1C ). Exosomes were purified and coupled to beads to analyze GFP-fluorescence and BAG6 expression by flow cytometry (Fig.1D ).
Exosomes from GFP-transfected cells showed background fluorescence (same level as untransfected cells), whereas a clear targeting of GFP to exosomes was observed for exosomes from GFP-BAG6 transfected cells indicating that BAG6 contains For personal use only. on October 28, 2017. by guest www.bloodjournal.org From exosome-targeting sequences (see bar diagram for quantitative results). In line, we observed an increase of BAG6 expression on exosomes upon GFP-BAG6 transfection ( Fig.1D , right histogram). To exclude potential interference of the GFPtag with the subcellular distribution and exosomal targeting of the proteins we performed analogous experiments with 6xhis-tagged constructs that confirmed the above data (not shown).
BAG6-expressing exosomes trigger NK cell cytotoxicity. Having established that
BAG6 is released via exosomes in vitro we were interested in the functional activity of BAG6-expressing exosomes. Since it is known that exosomes are released in response to the DNA damage-inducible p53-dependent secretory pathway [28] [29] [30] we first tested whether the release of BAG6-expressing exosomes was inducible from cells with an intact p53 pathway (293T cells). Exosomal BAG6 release was triggered in response to cellular stress signals (heat shock or doxorubicine) or upon inflammatory signals including TNFalpha or HDAC inhibition with valproate ( Fig.2A ).
Therefore, 293T cells were used to produce exosomes for NK cell stimulation. The overexpression of BAG6 on exosomes (as shown previously 25 ) was here confirmed by flow cytometry of the exosomes using a BAG6-specific antibody ( Fig.2B ) and a recombinant NKp30-Fc (data not shown). Exosomal marker proteins were detectable in exosomal lysates from wildtype and BAG6-overexpressing cells, however due to the detection threshold, BAG6 was only detectable by Western blotting in exosomes from BAG6-transfected cells (Fig.2C ). Healthy NK cells were incubated with exosomes derived from wildtype or BAG6 overexpressing cells and used in killing assays with the leukemic cell lines 697 and NALM6 as target cells (Fig.2D ).
Exosome-treated NK cells were able to kill these target cells that were initially resistant against NK cell lysis. The killing efficacy of NK cells treated with BAG6-overexpressing exosomes was even higher compared to NK cells treated with wild type exosomes and could be blocked with an NKp30 antibody ( Fig.2D ). cell killing assay using 293T wild type and transduced cells was performed. As expected, and previously described for other cell types 10, 12, 25 , target cells without BAG6 expression were more resistant against NK cell killing than parental wildtype cells or cells transduced with a control shRNA ( Fig.3B ).
BAG6 is mandatory for immune surveillance in a 293T
All three 293T cell lines (wt, ctrl, k.d.) were able to form tumors upon subcutaneous injection in SCID/beige mice deficient for B-, T-and NK cells, although tumor formation of the transduced cell lines was slightly delayed (Fig.3C ). This might reflect the slightly reduced proliferation rate of the transduced cells that we observed in vitro (not shown). The mice received either human PBMCs or PBS control injections one day after tumor cell inoculation. Only the wildtype and the control transduced cell lines were efficiently recognized and eliminated by PBMCs, whereas the BAG6 knockdown cell line was able to form tumors despite the presence of immune cells, For personal use only. on October 28, 2017. by guest www.bloodjournal.org From albeit at a slightly lesser incidence than PBS-injected animals but nevertheless statistically significant ( Fig.3C , suppl. Fig.3 ). Hence, the BAG6 knockdown triggered escape from immunological tumor surveillance demonstrating the role of exosomal BAG6 immunosurveillance in vivo.
Elevated plasma levels of NKp30-ligand BAG6 and ligands for NKG2D in CLL patients. A defective cytolytic activity of NK cells has recently been described in patients with CLL 15, 16, 20 . To assess the role of BAG6 for NK cell activity in this disease we measured BAG6 plasma levels in 86 primary CLL samples and in 50 age-matched healthy controls with ELISA. Surprisingly, CLL patients had significantly elevated levels of BAG6 compared to healthy donors. Moreover BAG6 level increased with progressed disease stage (Fig.4A ). Since a role for soluble NKG2D ligands in CLL is discussed 16, 17 we included in our analysis ligands for the activating NK cell receptor NKG2D (MICB, ULBP2 and MICA). Interestingly, we found significantly higher levels of MICB and ULBP2 in patients and levels increased with advanced disease stage (Fig.4B, C) . MICA was already discussed as a prognostic factor in CLL 17 . However we did not measure any significant overall difference in the expression levels of MICA in healthy versus CLL samples, although MICA plasma levels were significantly higher in CLL patients with advanced Binet stage C compared to Binet stage A (Fig.4D) . Taken together, patients with CLL showed elevated levels of soluble ligands for NKp30 and NKG2D in comparison to healthy individuals.
Soluble plasma factors from CLL patients impair NK cell function.
In cytotoxicity assays, the natural cytotoxic activity of NK cells is believed being mainly dependent on NKG2D and NCRs that synergize with CD16 33 . Having identified BAG6 as an extracellular ligand of the NCR NKp30, which activates NK cells 10 (Fig.2 ) and promotes immunosurveillance (Fig.3) , the overexpression of BAG6 in the plasma of CLL patients with impaired NK cell activity was quite unexpected. Hence, we tested the impact of plasma from CLL patients on natural cytotoxicity of NK cells. To this end, NK cells were purified from healthy donors and incubated over night with plasma derived from CLL patients or age-matched healthy volunteers. The cytotoxicity of plasma-treated and untreated NK cells (control) was assessed in killing assays using the Burkitt's lymphoma cell line Raji as target. Samples from healthy donors had only minor effects on NK cell cytotoxicity, whereas killing activity was eliminated upon incubation with CLL plasma (Fig.5A ). Flow cytometry (Fig.5B ) revealed that the activating receptors NKp30, NKp46 and NKG2D were not significantly modulated, although both, healthy-donor and CLL samples, induced a minor down-regulation of these receptors. Instead, a robust down-regulation of surface CD16 and CD56 was observed upon treatment of normal NK cells with CLL sera (Fig.5B) . Control experiments confirmed that the reduced CD16 expression was not due to a blocking of antibody binding by serum IgG (data not shown). Next, the plasma samples were fractionated into the soluble and vesicular part to test which of these fractions induced the NK cell inhibition. As expected, the different fractions of healthy samples did not alter the cytotoxicity of NK cells significantly, whereas the CLL plasmadependent inhibition was mainly mediated by soluble factors but not by the exosomal fraction (Fig.5C ). This is in line with our previous studies, which reported that recombinant, purified BAG6 inhibited TNFalpha and IFNgamma release from NK cells 10 as well as NK cell-cytotoxicity 25 . Collecting data from patients (n=6, Fig.5D ) revealed that the inhibition mediated by plasma and the soluble fractions was significant, whereas the exosomal fractions rather enhanced cytotoxicity, albeit the differences to the untreated control were minor and not significant.
BAG6 is released from CLL cells and cell lines as a soluble factor and suppresses NK cell cytotoxicity. To understand a possible contribution of BAG6 to
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From NK cell inhibition in CLL, we analyzed the distribution of BAG6 in soluble versus exosomal fractions in plasma of CLL patients (Fig.6A ). In healthy donor samples BAG6 was barely detectable and the protein was sequestered within the exosomal fraction. In marked contrast, most of the BAG6 protein accumulated in the soluble fraction of CLL patient plasma (Fig.6A ). BAG6 was also detectable in the soluble part of supernatant from suspension-cultured CLL cells, but barely in association with the exosomal fraction. The same amount of cultured B cells purified from healthy donors did not release much BAG6 (Fig.6B) . The fractionation of the supernatant from CLL cell lines JVM-3 and MEC-1 revealed a similar distribution with high levels of the soluble protein. However 293T cells and MCF7 cells released the exosomal form ( Fig.6C, see Fig. 2B ).
Next, we pre-incubated NK cells with plasma from a healthy donor or the same plasma supplemented with recombinant, soluble BAG6 protein to confirm that the soluble protein added to plasma inhibited NK cell cytotoxicity. An inhibitory effect of purified soluble BAG6 on NK cell activity was observed previously 25 . NK cells preincubated with plasma supplemented with soluble BAG6 had a lower killing ability than the controls, as expected ( Fig.6D ). Vice versa, depletion of BAG6 from CLL plasma using BAG6-specific affinity chromatography was sufficient to rescue NK cell cytotoxicity at least partly (Fig.6E, right bar) .
The killing of Raji cells by untreated NK cells was mainly dependent on NKp30 as
blocking of NKp30 but not NKG2D diminished cell lysis significantly (Fig.6E, grey bars). Vice versa, depletion of ligands for NKG2D using NKG2D-Fc increased target cell killing only slightly, whereas depletion of NKp30-ligands with NKp30-Fc or a BAG6-specific antibody resulted in a rescue of the plasma-mediated NK cell inhibition ( Fig.6E, black bars) . Together these data suggest that soluble BAG6, in contrast to the exosomal form, inhibits NK cell function in CLL.
Discussion
The activation of NK cells is carefully orchestrated by activating and inhibitory signals. In this report we used primary CLL samples to show that soluble plasma factors were responsible for the inhibition of NK cell cytotoxicity (Fig.6 ). We could further attribute the inhibitory activity to high levels of soluble BAG6 (NKp30 ligand) in CLL patient plasma, which increased with disease progression (Fig.4 and 6 ).
Recombinant BAG6 was previously shown to activate NK cells when immobilized whereas it inhibited NK cell cytotoxicity in its soluble form 25 reflecting the scenario in CLL. Using biochemical and functional assays we proved that BAG6 ligand was secreted via the exosomal pathway ( Fig.1 ) and further showed that only this exosomal form was able to activate NK cell cytotoxicity (Fig.2) . These data suggest that the activation through tumor cell-derived, BAG6-expressing exosomes is defective in CLL, resulting in both lack of NK cell activation and suppression of the cytolytic activity ( Fig.3 and 6 ). BAG6-positive exosomes represent not only a trigger for cytotoxicity but have also been shown to induce the secretion of pro-inflammatory cytokines from NK cells 25 .
The release of exosomes is dependent on a functional p53-mediated DNA damage response [28] [29] [30] and we used p53-intact cell lines capable to release BAG6-positive exosomes for the experiments (Fig.2A) . Genetic lesions affecting the DNA damage response are frequent in CLL, probably explaining a dysfunction of exosome formation in this disease. In addition, the ceramide pathway is also mandatory for exosome release and mutations for the rate limiting enzyme nSmase2 (SMPD3) are reported in leukemia 34 . However, prospective studies with genetically defined patient samples are necessary to establish a correlation of an impaired DNA-or ceramidepathway and BAG6 plasma level. As the 86 CLL patient samples were only partly characterized with respect to p53 status and contained just 4 cases with 17p
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From deletion, it was not possible to analyze an association of BAG6 levels with p53 mutations/deletions.
There is emerging evidence that exosomes may direct the function and fate of bystander cells via transport of proteins and RNAs and thus modulate the tumor microenvironment 35, 36 . Exosomes secreted by tumor cells were described in several studies as immune suppressors, promoting tumor progression and immune evasion 35, 36 . However, not much was known about the mechanisms explaining how exosomes activate NK cells and confer antitumor activity, although a role of HSP70 was discussed [37] [38] [39] [40] . Here, we propose a crucial role for NKp30/BAG6 in exosomemediated NK cell activation, as tumor cells, which fail to release BAG6-positive exosomes, circumvent immune detection in a xenograft model (Fig.3C ).
In addition to BAG6, other factors known to compromise NK cell function were also elevated in CLL patients including macrophage migration inhibitory factor (MIF) 41 (suppl. Fig.4 ) and soluble ligands for NKG2D (MICA/B and ULBP2) ( Fig.4 ). This is in line with a recent study, which described a prognostic relevance for soluble ULBP2 level for the therapy-free survival of CLL patients 17 . A role for NKG2D was also suggested for the elimination of CLL cells by Vdelta1 T lymphocytes that may attenuate the progression of the disease 42 . Interestingly, neither any of these studies nor an independent report 15 demonstrate diminished NKG2D surface expression on NK cells from CLL patients, although an association of sMICA levels with the downmodulation of NKG2D surface expression on CD8 T cells was recently described for CLL 43 . It is still controversially discussed whether the immune escape through soluble NKG2D ligands is due to a passive blocking of the receptor, or rather to an active down-regulation of NKG2D on effector cells 6, 44 . Here, we report that CLL plasma did not cause a significant down-regulation of NKG2D on healthy donor NK cells, despite For personal use only. on October 28, 2017. by guest www.bloodjournal.org From of high expression of soluble NKG2D ligands (Fig.4B-D) . However, this might be different in other tumor entities e.g. AML 16 or Hodgkin lymphoma 45 .
The only variation so far reported for NK cells from CLL patients compared to NK cells from healthy donors is a slight but significant down-regulation of NKp30 15 . A decreased expression of NCRs on NK cells correlating to poor prognostic factors was also reported 20 . A critical role for NKp30 for immune surveillance was already proposed but just recently demonstrated in gastrointestinal tumors 46 . Inhibitory NKp30 splice variants were identified that affected the prognosis of gastrointestinal sarcoma upon treatment with NK cell-stimulatory KIT tyrosine kinase inhibitors 46 . Complementary, we uncover a not yet described role for the NKp30ligand BAG6 in anti-tumor immunity in CLL. This is in line with a concept suggesting that the lack of activating NK cell ligands (either on target cells or on released exosomes) results in a failure of "induced self activation" of NK cells. This means that activation of NK cells by extracellular ligands "in trans" is possible, which poses the question how NK cells may retain their specificity against the damaged (and exosomes releasing) target cells. One possible explanation is that NK cells need a second signal as previously discussed 47, 48 , which is delivered by direct cell-cell contact. The ability of tumor cells to deliver this activation is probably lost during tumor progression, as suggested in the Burkitt's lymphoma Eμ-myc mouse model 48 .
Based on our data we propose that the first signal delivered by damaged or transformed target cells relates to exosomes that present activating ligands such as BAG6. A failure of exosome stimulation results in NK cell anergy, further driven by soluble inhibitory factors in the microenvironment (see Fig. 7 ). This model convincingly explains why CLL cells are resistant to resting NK cells, but are sensitive towards activated NK cells 15 . Moreover, it opens up potential therapeutic strategies using exosomes as immunotherapeutic agents to restore NK cell function in CLL For personal use only. on October 28, 2017. by guest www.bloodjournal.org From patients. In conclusion, our data suggest that exosomal BAG6 represents a crucial component of "induced self activation" of NK cells, which is impaired in CLL contributing to immune escape in this disease. 
Figure legends
